1
|
Desai KG, Sofa C, Wang N, Mandal B, Blockus B, Heacock N, Colandene JD. Feasibility of Laboratory Equipment-Based Simulation Methods to Assess the Impact of Vehicle Transportation on Product Quality of mAb Dosing Solutions. Mol Pharm 2024; 21:4726-4746. [PMID: 39141808 DOI: 10.1021/acs.molpharmaceut.4c00681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/16/2024]
Abstract
Therapeutic monoclonal antibody (mAb) products for intravenous (IV) administration generally require aseptic compounding with a commercially available diluent. When the administration site is located away from the preparation site, the prepared dosing solution may need to be transported in a vehicle. The impact of vehicle transportation on the product quality of mAbs needs to be evaluated to define safe handling and transportation conditions for dosing solutions. The design and execution of actual vehicle transportation studies require considerable resources and time. In this study, we systematically developed three different laboratory equipment-based methods that simulate vehicle transportation stresses: orbital shaker (OS), reciprocating shaker (RS), and vibration test system (VTS)-based simulation methods. We assessed their feasibility by comparing the impact on product quality caused by each simulated method with that caused by actual vehicle transportation. Without residual polysorbate 80 (PS80) in the mAb dosing solution, transportation via a cargo van led to a considerable increase in the subvisible particle counts and did not meet the compendial specifications for the light obscuration method. However, the presence of as low as 0.0004%w/v (4 ppm) PS80 in the dosing solution stabilized the mAb against vehicle transportation stresses and met the compendial specifications. Vehicle transportation of an IV bag with headspace resulted in negligible micro air bubbles and foaming in both PS80-free and PS80-containing mAb dosing solutions. These phenomena were found to be comparable to the VTS-based simulated method. However, the OS- and RS-based simulated methods formed significantly more micro air bubbles and foaming in an IV bag with headspace than either actual vehicle transportation or the VTS-based simulated method. Despite the higher interfacial stress (micro air bubbles and foaming) in the dosing solution created by the OS- and RS-based simulated methods, 0.0004%w/v (4 ppm) PS80 in the dosing solution was found to be sufficient to stabilize the mAb. The study shows that under appropriate simulated conditions, the OS-, RS-, and VTS-based simulated methods can be used as practical and meaningful models to assess the impact and risk of vehicle transportation on the quality of mAb dosing solutions.
Collapse
Affiliation(s)
- Kashappa Goud Desai
- Drug Product Development - Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Ave, Collegeville, Pennsylvania 19426, United States
| | - Cait Sofa
- Drug Product Development - Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Ave, Collegeville, Pennsylvania 19426, United States
| | - Ning Wang
- Drug Product Development - Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Ave, Collegeville, Pennsylvania 19426, United States
| | - Bivash Mandal
- Drug Product Development - Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Ave, Collegeville, Pennsylvania 19426, United States
| | - Brendan Blockus
- Drug Product Development - Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Ave, Collegeville, Pennsylvania 19426, United States
| | - Nathan Heacock
- Drug Product Development - Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Ave, Collegeville, Pennsylvania 19426, United States
| | - James D Colandene
- Drug Product Development - Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Ave, Collegeville, Pennsylvania 19426, United States
| |
Collapse
|
2
|
Kumar A, Ramesh S, Walther-Jallow L, Goos A, Kumar V, Ekblad Å, Madhuri V, Götherström C. Successful transport across continents of GMP-manufactured and cryopreserved culture-expanded human fetal liver-derived mesenchymal stem cells for use in a clinical trial. Regen Ther 2024; 26:324-333. [PMID: 39027723 PMCID: PMC11255121 DOI: 10.1016/j.reth.2024.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2024] [Revised: 06/07/2024] [Accepted: 06/13/2024] [Indexed: 07/20/2024] Open
Abstract
Introduction Cell therapy has been increasingly considered to treat diseases, but it has been proven difficult to manufacture the same product at multiple manufacturing sites. Thus, for a wider implementation an alternative is to have one manufacturing site with a wide distribution to clinical sites. To ensure administration of a good quality cell therapy product with maintained functional characteristics, several obstacles must be overcome, which includes for example transfer of knowledge, protocols and procedures, site assessment, transportation and preparation of the product. Methods As the preparatory work for a clinical trial in India using fetal mesenchymal stem cells (fMSCs) developed and manufactured in Sweden, we performed a site assessment of the receiving clinical site, transferred methods, developed procedures and provided training of operators for handling of the cell therapy product. We further developed a Pharmacy Manual to cover the management of the product, from ordering it from the manufacturer, through transport, reconstitution, testing and administration at the clinical site. Lastly, the effect of long-distance transport on survival and function of, as well as the correct handling of the cell therapy product, was evaluated according to the pre-determined and approved Product Specification. Results Four batches of cryopreserved human fetal liver-derived fMSCs manufactured according to Good Manufacturing Practice and tested according to predetermined release criteria in Sweden, were certified and transported in a dry shipper at -150 °C to the clinical site in India. The transport was temperature monitored and took three-seven days to complete. The thawed and reconstituted cells showed more than 80% viability up to 3 h post-thawing, the cell recovery was more than 94%, the cells displayed the same surface protein expression pattern, differentiated into bone, had stable chromosomes and were sterile, which conformed with the data from the manufacturing site in Sweden. Conclusions Our study shows the feasibility of transferring necessary knowledge and technology to be able to carry out a clinical trial with a cell therapy product in distant country. It also shows that it is possible to transport a cryopreserved cell therapy product over long distances and borders with retained quality. This extends the use of cryopreserved cell therapy products in the future.
Collapse
Affiliation(s)
- Ashis Kumar
- Department of Paediatric Orthopaedics, Christian Medical College, Vellore 632 004, Tamil Nadu, India
- Center for Stem Cell Research, a Unit of in Stem Bengaluru, Christian Medical College, Vellore 632 002, Tamil Nadu, India
- Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram 695011, Kerala, India
| | - Sowmya Ramesh
- Department of Paediatric Orthopaedics, Christian Medical College, Vellore 632 004, Tamil Nadu, India
- Center for Stem Cell Research, a Unit of in Stem Bengaluru, Christian Medical College, Vellore 632 002, Tamil Nadu, India
| | - Lilian Walther-Jallow
- Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Annika Goos
- Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Vignesh Kumar
- Department of Paediatric Orthopaedics, Christian Medical College, Vellore 632 004, Tamil Nadu, India
- Center for Stem Cell Research, a Unit of in Stem Bengaluru, Christian Medical College, Vellore 632 002, Tamil Nadu, India
| | - Åsa Ekblad
- Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Vrisha Madhuri
- Department of Paediatric Orthopaedics, Christian Medical College, Vellore 632 004, Tamil Nadu, India
- Center for Stem Cell Research, a Unit of in Stem Bengaluru, Christian Medical College, Vellore 632 002, Tamil Nadu, India
- Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram 695011, Kerala, India
| | - Cecilia Götherström
- Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
3
|
James LP, Kimberly R, Lindsell CJ, Meinzen-Derr JK, O’Hara R. Scientia pro bono humani generis: Science for the benefit of humanity. J Clin Transl Sci 2024; 8:e29. [PMID: 38384907 PMCID: PMC10879989 DOI: 10.1017/cts.2023.696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 12/06/2023] [Accepted: 12/06/2023] [Indexed: 02/23/2024] Open
Affiliation(s)
- Laura P. James
- University of Arkansas for Medical Sciences (UAMS) and Arkansas Children’s Hospital, Little Rock, AR, USA
| | - Robert Kimberly
- University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA
| | | | - Jareen K. Meinzen-Derr
- Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Center for Clinical and Translational Science and Training, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Ruth O’Hara
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
4
|
Tenaerts P, Hernandez AF, Lipset C. Clinical trial site readiness for decentralized trials - fitting trials into today's world. J Clin Transl Sci 2024; 8:e43. [PMID: 38476244 PMCID: PMC10928696 DOI: 10.1017/cts.2024.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 01/11/2024] [Accepted: 01/24/2024] [Indexed: 03/14/2024] Open
Affiliation(s)
| | | | - Craig Lipset
- Clinical Innovation Partners, Basking Ridge,
NJ, USA
- Decentralized Trials & Research Alliance, San
Diego, CA, USA
| |
Collapse
|
5
|
Carter-Edwards L, Hidalgo B, Lewis-Hall F, Nguyen T, Rutter J. Diversity, equity, inclusion, and access are necessary for clinical trial site readiness. J Clin Transl Sci 2023; 7:e268. [PMID: 38380391 PMCID: PMC10877510 DOI: 10.1017/cts.2023.660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 09/19/2023] [Accepted: 10/18/2023] [Indexed: 02/22/2024] Open
Affiliation(s)
- Lori Carter-Edwards
- Kaiser Permanente Bernard J Tyson School of Medicine,
Pasadena, CA, USA
- The University of North Carolina at Chapel Hill Gillings School of Global
Public Health, Chapel Hill, NC,
USA
| | - Bertha Hidalgo
- The University of Alabama at Birmingham, Birmingham,
AL, USA
| | | | - Tung Nguyen
- University of California San Francisco, San
Francisco, CA, USA
| | - Joni Rutter
- National Center for Advancing Translational Sciences,
Bethesda, MD, USA
| |
Collapse
|